Press Releases

MIRA LOMA, Calif., Nov. 14, 2019 /PRNewswire/ -- Bridgecom, provider of a standardized colorectal cancer (CRC) screening outreach program which accelerates patient compliance, will be at

WASHINGTON, Nov. 14, 2019 /PRNewswire/ -- A new analysis of publicly reported financial data by researchers at West Health Policy Center and

SUZHOU, China and ROCKVILLE, Md., Nov. 14, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the updated preliminary results from a Phase I clinical trial on the compan

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Highlights

UPPSALA, Sweden, Nov. 14, 2019 /PRNewswire/ -- Sweden's first-ever patient to be treated on the groundbreaking Elekta Unity MR-Linac radiation therapy system took place at Uppsala University Hospital yesterday. Elekta Unity gives doctors the "vision" to zero in on tumors and avoid healthy tissues and thereby

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, announced today that it will establish an integrated online and offline healthcare retail channel with HEC Group ("HEC"). The channel will be used to expand the offering of HEC's products and resources to more patients

STOCKHOLM, Nov. 14, 2019 /PRNewswire/ -- The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, ("Oncopeptides" or the "Company") are hereby given notice to attend an Extraordinary General Meeting to be held at Tändstickspalatset, Västra Trädgårdsg

STOCKHOLM, Nov. 14, 2019 /PRNewswire/ -- "Since the US is the world's largest market for neurosurgical procedures, we have focused much of our team's resources toward supporting a successful early market introduction. Response to our IRRAflow technology remains strong, and our sales funnel is full. Patient treatments with IRRAflow continued to increase, and mul

STOCKHOLM, Nov. 14, 2019 /PRNewswire/ -- "Following a record first half year, sales weakened in the third quarter. However, the market situation and demand for our products remain favorable and we have confidence in our strategy" Johan Löf, CEO of RaySearch. Comments on page 2.THIRD QUARTER (JULY-

STOCKHOLM, Nov. 14, 2019 /PRNewswire/ -- "This third quarter of 2019 saw us move steadily towards full recruitment of the NefIgArd study, despite a somewhat slower pace during the summer months. We can now see the finish line and we hope that the next couple of months develop as planned so that we can achieve our ambitious goal.  Due to our interactions with the FDA